Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of <i>MTAP</i>-Deleted Cancers-Reference-Cited by-同舟云学术

Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of MTAP-Deleted Cancers

Published:2022-01-18 Issue:3 Volume:65 Page:1749-1766
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Smith Christopher R.¹^ORCID,Aranda Ruth¹,Bobinski Thomas P.²,Briere David M.¹,Burns Aaron C.¹,Christensen James G.¹,Clarine Jeffery¹,Engstrom Lars D.¹,Gunn Robin J.¹,Ivetac Anthony¹,Jean-Baptiste Ronald³,Ketcham John M.¹,Kobayashi Masakazu³,Kuehler Jon¹,Kulyk Svitlana¹,Lawson J. David¹,Moya Krystal¹,Olson Peter¹,Rahbaek Lisa¹,Thomas Nicole C.¹,Wang Xiaolun¹,Waters Laura M.¹,Marx Matthew A.¹

Affiliation:

1. Mirati Therapeutics, San Diego, California 92121, United States

2. DSG, San Diego, California 92130, United States

3. ZoBio BV, J. H. Oortweg 19, 2333 CH Leiden, Netherlands

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c01900

Reference49 articles.

1. Protein Arginine Methylation in Mammals: Who, What, and Why